HCB301 for Advanced Solid Tumors and Hodgkin Lymphoma
This study is testing a new treatment called HCB301 for people with advanced solid tumors or Hodgkin lymphoma that has come back or not responded to other treatments. The main goal is to see how safe HCB301 is and what side effects (unwanted effects) might occur. Researchers also want to find the highest dose that can be given safely. You might be able to join if you are 18 or older, have one of these conditions, and standard treatments are no longer an option. The study will also look at how well HCB301 works, but the primary focus is on safety and finding the right dose.
- Study design
- This is a Phase 1, open-label study, meaning both you and the study team will know you are receiving HCB301. It plans to enroll about 50 participants.
- What's involved
- You will receive HCB301 through an intravenous (IV) infusion. You will continue treatment until side effects become too severe, your disease gets worse, you withdraw consent, or the study ends.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track safety and dose information for 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
At a glance
Conditions
Where it's being run
7 sites across 3 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number/incidence and percentage of subjects with adverse events, including ADA.12 months
To evaluate the safety and tolerability of HCB301.
- Number of subjects with MTD and RDE of HCB301.12 months
To determine the MTD and RDE.